Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 15/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 11/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 2/20 | 0.40 |
| ▸ | CCR7 | P32248 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30631983 | 1.00 | CXCR2 (0.49) | CXCR2GAAPOLBCXCR1MAPT | |
| SCHEMBL13075315 | 0.89 | CXCR2 (0.57) | CXCR2GAAPOLBCXCR1MAPT | |
| SCHEMBL30631981 | 0.89 | CXCR2 (0.57) | CXCR2GAAPOLBCXCR1MAPT | |
| SCHEMBL23610482 | 0.89 | CXCR2 (0.57) | CXCR2GAAPOLBCXCR1MAPT | |
| SCHEMBL21803167 | 0.87 | GAA (0.50) | CXCR2GAAPOLBCXCR1MAPT | |
| SCHEMBL30631989 | 0.87 | GAA (0.50) | CXCR2GAAPOLBCXCR1MAPT | |
| SCHEMBL23220275 | 0.82 | CXCR2 (0.48) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL12261147 | 0.82 | CXCR2 (0.63) | CXCR2GAACXCR1CCR6 | |
| SCHEMBL21803113 | 0.73 | GAA (0.51) | CXCR2GAAPOLBMAPT | |
| SCHEMBL20732789 | 0.72 | GAA (0.60) | CXCR2GAAPOLBCXCR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312344-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240368144-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-116874466-A | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | 辉瑞公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-112672791-B | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | 辉瑞公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11708360-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2021-07-08 | — | — | US | disclosed |
| CN-112672791-A | N-substituted dioxocyclobutenylamino-3-hydroxy-pyridinecarboxamides useful as CCR6 inhibitors | 辉瑞公司 | 2021-04-16 | — | — | CN | disclosed |
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200095239-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | CXCR2 13/4885GAA 4066/4885POLB 3443/4885 |
| US-20240368144-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | CXCR2 13/4885GAA 4066/4885POLB 3443/4885 |
| US-11708360-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | CXCR2 13/4885GAA 4066/4885POLB 3443/4885 |
| US-20200095239-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | CXCR2 13/4885GAA 4066/4885POLB 3443/4885 |
| US-12312344-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | CXCR2 13/4885GAA 4066/4885POLB 3443/4885 |
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | CXCR2 13/4885GAA 4066/4885POLB 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.